The proteinase K market is expected to register a CAGR of nearly 3% during the forecast period, 2021-2026. The rising burden of chronic disorders and infectious diseases and growing applications of diagnostic techniques and their associated enzymes for IVD are among key trends that are expected to trigger the market growth.
Proteinase K has a great potential in the detection of COVID-19, which is also anticipated to provide growth avenues to the market. As per a study titled, "Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA", published in December 2020, simple proteinase K treatment and repetitive heating steps with a sensitivity of 94.6% were compared with kit-based isolation methods. It was found out that the proteinase K method can be considered as a convenient and efficient method for extraction of SARS-CoV-2 RNA.
Chronic diseases are the most prevalent health condition globally. Chronic diseases include cancer, diabetes, hypertension, stroke, heart disease, respiratory diseases, arthritis, and obesity, which lead to hospitalization, long-term disability, reduced quality of life, and even death. According to the GLOBOCAN 2020, the 5-year prevalence for cancer was reported to be around 50,550,287 worldwide, and about 9,958,133 deaths due to cancer were recorded globally. The rising prevalence of cancer has led to an increase in next-generation sequencing and polymerase chain reaction applications.
Furthermore, the increasing research and development activities and investments by research institutes and pharmaceutical and biopharmaceutical companies in innovation help the market to grow. However, the availability of new sophisticated technologies for DNA purification may hamper the growth of the proteinase K market.
Key Market Trends
The Infectious Diseases Segment is Expected to Dominate the Market Over the Forecast Period
The infectious diseases segment is found to dominate the proteinase K market that has been attributed to the increasing prevalence of infectious diseases and the wide applicability of proteinase K in the diagnosis of various infectious diseases.
With the rising COVID-19 cases, there is wide adoption of the enzyme in COVID-19 diagnostics, which is expected to contribute to the dominant share of the segment throughout the forecast period.
There is also a rising number of infectious diseases that have helped in boosting the overall market growth. For instance, as per the Global Tuberculosis (TB) Report 2019, the incidence of TB in low-income regions was higher during 2018, whereas in the developed regions, it was comparatively low. The report has also suggested that the incidence of TB in Africa was around 2,450,000, whereas, in the Americas, it was around 289,000.
According to the World Health Organization 2019 Report, there is also a high burden of infectious diseases, including HIV, TB, malaria, hepatitis B, and neglected tropical diseases, that are found to be higher in low-income countries compared to the high-income countries. Globally, in 2017, the incidence rate of new HIV infections was 1.09 times higher in men than in women.
Moreover, several studies show that incubation of DNA for the hepatitis B virus with proteinase K results in efficient DNA isolation. The DNA yield from this proteinase K is being increased by 5 times compared to standard procedures that do not require proteinase K. Thus, the wide applicability of proteinase K in the diagnosis of several infectious diseases is a key factor that helps the market grow.
North America Represents the Largest Market During the Forecast Period
North America is found registering high growth in the region due to the increasing number of cancer and infectious diseases and growing next-generation sequencing and polymerase chain reaction applications that are found boosting the market growth in the region. This is expected to drive the demand for proteinase K required in NGS and PCR techniques.
Moreover, with the emergence of COVID-19, the use of proteinase K registered increased, and therefore, new products were developed, which impacted the market positively. For instance, in May 2020, Zymo research received an Emergency Use Authorization by the United States Food & Drug Administration for "Quick SARS-CoV-2 rRT-PCR Kit" that includes "Proteinase K w/ Storage Buffer set". Such product approvals are expected to boost the demand for proteinase K.
According to the United States' National Center for Health Statistics, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of the country, and by 2020, it is projected to grow to an estimated 157 million, with 81 million having multiple conditions.
According to the Centers for Disease Control and Prevention's (CDC) 2018 report on "Disease rates and the number of new cases", the number of new cases and rate of many infectious diseases have increased in the recent decades. The number of new cases of Acute hepatitis A, B, and C viral infection was 1670, 3374, and 849 in 2010, respectively. The data reports that the number of new cases increased to 3365, 3409, and 4225 in 2017, respectively.
According to the Pharmaceutical Research and Manufacturers Association (PhRMA), 2018, US firms conduct over half the world's R&D in pharmaceuticals. Approximately 79.6 billion was invested in biopharmaceutical research and development in the United States in 2018. Therefore, all these factors are found creating high growth opportunities for proteinase K in the North American region.
The proteinase K market is moderately competitive and few of the major players are currently dominating the market. Some of the companies currently dominating the market are Merck KGaA, F. Hoffmann-La Roche Ltd, Advanced Enzyme Technologies, Biocatalysts, Thermo Fisher Scientific, Klee GmbH, Dyadic International, and QIAGEN. The key players in the market are involved in novel product launches, acquisitions, collaborations, partnerships, and geographical expansions to reinforce their market presence.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Rising Burden of Chronic and Infectious Diseases
- 4.2.2 Growing Applications of Diagnostic Techniques and their Associated Enzymes for IVD
- 4.3 Market Restraints
- 4.3.1 Availability of New Sophisticated Technologies for DNA Purification
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Form
- 5.1.1 Powder
- 5.1.2 Liquid
- 5.2 By Therapeutic Area
- 5.2.1 Infectious Diseases
- 5.2.2 Diabetes
- 5.2.3 Oncology
- 5.2.4 Cardiology
- 5.2.5 Other Therapeutic Areas
- 5.3 Geography
- 5.3.1 North America
- 188.8.131.52 United States
- 184.108.40.206 Canada
- 220.127.116.11 Mexico
- 5.3.2 Europe
- 18.104.22.168 Germany
- 22.214.171.124 United Kingdom
- 126.96.36.199 France
- 188.8.131.52 Italy
- 184.108.40.206 Spain
- 220.127.116.11 Rest of Europe
- 5.3.3 Asia-Pacific
- 18.104.22.168 China
- 22.214.171.124 Japan
- 126.96.36.199 India
- 188.8.131.52 Australia
- 184.108.40.206 South Korea
- 220.127.116.11 Rest of Asia-Pacific
- 5.3.4 Rest of the World
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Merck KGaA
- 6.1.2 F. Hoffmann-La Roche Ltd
- 6.1.3 Advanced Enzymes Technologies
- 6.1.4 Biocatalysts Ltd
- 6.1.5 Thermo Fisher Scientific
- 6.1.6 Klee GmbH
- 6.1.7 Dyadic International
- 6.1.8 QIAGEN
- 6.1.9 Cell Signalling Technology Inc.
- 6.1.10 Danaher Corporation (Leica Biosystems)
- 6.1.11 Geno Technology Inc. (G Bioscience)
- 6.1.12 Amicogen
- 6.1.13 A & A Biotechnology
- 6.1.14 bioWORLD
- 6.1.15 New England Biolabs
- 6.1.16 Promega Corporation
- 6.1.17 Avantor
7 MARKET OPPORTUNITIES AND FUTURE TRENDS